Australian biotech market watch 28/09/09
Monday, 28 September, 2009
The ASX200 opened sharply lower as expected, and was sitting at 4659 at 11:00am.
Among the pharmaceutical stocks, market heavyweight CSL Limited (ASX:CSL) was down 52c to $33.85
Photoprotective drug manufacturer, Clinuvel Pharmaceuticals (ASX:CUV) slumped nearly 6% to 31.5c after releasing its full year financial results – a 32% drop in revenues and a loss of $15.3M
Cellistis Limited (ASX:CST) fared little better, dropping 12c to $3.25 despite its recent announcement of a record $8.2M annual profit. The Cellistis share price had recently spiked as high as $4.00 and had more than tripled since February.
More positive numbers for Acrux (ASX:ACR) up almost 5% to $1.58 and Chemgenex (ASX:CXS) up almost 4% to 78.5c
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
Intense grief linked to higher risk of death for a decade
Researchers have found that bereaved people with persistent high levels of intense grief use more...
